Continuation rates of oral hormonal contraceptives in a cohort of first-time users: A population-based registry study, Sweden 2005-2010

BMJ Open

Volumn 3, Issue 10, 2013, Pages

  Josefsson, Ann ^a,b   Wiréhn, Ann Britt ^a,b,c   Lindberg, Malou ^a,c   Foldemo, Anniqa ^a,c   Brynhildsen, Jan ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Department of Clinical Immunology and Transfusion Medicine   (Sweden)

^c Local Health Care Research and Development Unit   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; DRUG FORMULATION; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MIDWIFE; ORAL CONTRACEPTIVE USE; PHYSICIAN; POPULATION RESEARCH; PRESCRIPTION; REVIEW; RISK FACTOR; SWEDEN;

EID: 84886681845     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003401     Document Type: Review

References (26)

1. Trussell J. Understanding contraceptive failure. Best Pract Res Clin Obstet Gynaecol 2009;23:199-209.
2. Lindh I, Blohm F, Andersson-Ellström E, et al. Contraceptive use and pregnancy outcome in three generations of Swedish female teenagers from the same urban population. Contraception 2009;80:163-9.
3. Larsson M, Tydén T, Hanson U, et al. Contraceptive use and associated factors among Swedish high school students. J Contracept Reprod Health Care 2007;12:119-24. (Pubitemid 46897770)
4. Lawrie TA, Helmerhorst FM, Maitra NK, et al. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev 2011;11:CD004861.
5. Maitra N, Kulier R, Bloemenkamp KW, et al. Progestogens in combined oral contraceptives for contraception. Cochrane Database Syst Rev 2004;3:CD004861.
6. Update in Cochrane Database Syst Rev 011;5:CD004861.
7. Foster DG, Parvataneni R, de Bocanegra HT, et al. Number of oral contraceptive pill packages dispensed, method continuation, and costs. Obstet Gynecol 2006;108:1107-14. (Pubitemid 44665404)
8. Potter JE, McKinnon S, Hopkins K, et al. Continuation of prescribed compared with over-the-counter oral contraceptives. Obstet Gynecol 2011;117:551-7.
9. Sucato GS, Land SR, Murray PJ, et al. Adolescents' experiences using the contraceptive patch versus pills. J Pediatr Adolesc Gynecol 2011;24:197-203.
10. Murphy PA, Brixner D. Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. Contraception 2008;77:257-63.
11. Van Vliet HA, Grimes DA, Lopez LM, et al. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2011;9:CD003553.
12. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-35. (Pubitemid 47180362)
13. Kirkwood BR, Sterne JAC. Essential medical statistics. 2nd edn. Oxford: Blackwell ScienceLtd, 2003.
14. Swedish National Board of Health and Welfare. http://www.socialstyrelsen. se/statistik/statistikdatabas. Retrieved December 2012.
15. Wilson NM, Laursen M, Lidegaard Ø. Oral contraception in Denmark 1998-2010. Acta Obstet Gynecol Scand 2012;91:810-15.
16. Hall KS, Trussell J, Schwarz EB. Progestin-only contraceptive pill use among women in the United States. Contraception 2012;86:653-8.
17. Swedish National Board of Health and Welfare. http://www.socialstyrelsen. se/statistik/statistikefteramne/aborter. Retrieved November 2012.
18. Robinson JC, Plichta S, Weisman CS, et al. Dysmenorrhea and use of oral contraceptives in adolescent women attending a family planning clinic. Am J Obstet Gynecol 1992;166:578-83.
19. Lidegaard O, Nielsen LH, Skovlund CW, et al. Venous thrombosis in users of non-hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012;344:e2990.
20. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151.
21. Parkin L, Sharples K, Hernandez RK, et al. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;342: d2139.
22. Lidegaard Ø, Milsom I, Geirsson RT, et al. Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand 2012;9:769-78.
23. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-54. (Pubitemid 46551071)
24. Dinger J, Assmann A, Möhner S, et al. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 2010;36:123-9.
25. Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. J Fam Plann Reprod Health Care 2010;36:33-8.
26. Dinger J, Shapiro S. Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets. J Fam Plann Reprod Health Care 2012;38:2-6.